Table 3.

Baseline IGF-I and percentage of adherence regarding IGF-I levels after starting treatment with easypod™ (IGF-I levels were not associated with percentage of adherence).

	IGF-I laboratory range	Number of patients regarding IGF-I (%)
		Total	Prepubertal	Pubertal	GHD	SGA
Baseline IGF-I	Above	3 (1.3)	2 (0.9)	1 (3.9)	1 (0.7)	1 (1.2)
	Within	144 (60.5)	127 (59.9)	17 (65.4)	75 (52.1)	62 (72.1)
	Below	69 (29.0)	64 (30.2)	5 (19.2)	55 (38.2)	14 (16.3)
		Adherence, mean % (s.d.)
		Total	Prepubertal	Pubertal	GHD	SGA
After 6 months	Above	98.2 ± 2.3	98.6 ± 2.2	96.6 ± 2.1	97.7 ± 2.4	100.0
	Within	97.0 ± 10.0	97.4 ± 10.1	93.6 ± 9.3	96.2 ± 13.0	98.0 ± 2.9
	Below	98.3 ± 2.6	98.0 ± 2.7	100.0	98.0 ± 2.7	100.0
After 1 year	Above	97.6 ± 4.4	97.6 ± 4.8	97.7 ± 2.3	97.5 ± 5.2	97.7 ± 3.2
	Within	96.5 ± 11.9	96.3 ± 12.5	97.9 ± 2.6	95.8 ± 14.6	97.3 ± 6.4
	Below	92.2 ± 15.4	92.2 ± 15.4	N.A.	92.2 ± 15.4	N.A.
After 2 years	Above	91.0 ± 24.1	90.9 ± 25.3	91.4 ± 15.7	91.4 ± 24.4	89.2 ± 26.5
	Within	95.4 ± 11.4	95.3 ± 11.9	96.4 ± 3.4	95.0 ± 13.6	95.9 ± 6.8
	Below	87.1 ± 12.1	87.1 ± 12.1	N.A.	87.1 ± 12.1	N.A.
After 3 years	Above	98.2 ± 1.9	98.2 ± 1.9	N.A.	98.2 ± 2.4	98.3 ± 1.6
	Within	93.6 ± 15.7	93.4 ± 16.1	96.8 ± 2.0	95.7 ± 9.3	87.9 ± 25.7
	Below	N.A.	N.A.	N.A.	N.A.	N.A.
After 4 years	Above	96.0 ± 3.5	96.0 ± 3.5	N.A.	96.0 ± 3.5	96.2 ± 5.1
	Within	98.2 ± 1.6	98.2 ± 1.6	N.A.	99.2 ± 0.7	97.9 ± 1.8
	Below	96.4	96.4	N.A.	96.4	N.A.

GHD, growth hormone deficiency; IGF-I, insulin-like growth factor I; N.A., not available (n = 0); s.d., standard deviation; SGA, small for gestational age.